Loading...
XNAS
EKSO
Market cap11mUSD
Jul 25, Last price  
4.82USD
1D
2.12%
1Q
990.50%
Jan 2017
-91.93%
IPO
-98.05%
Name

Ekso Bionics Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
0.65
EPS
Div Yield, %
Shrs. gr., 5y
33.28%
Rev. gr., 5y
5.19%
Revenues
18m
-1.94%
2,706,0003,302,0005,327,0008,661,00014,221,0007,353,00011,332,00013,917,0008,882,00011,246,00012,912,00018,279,00017,925,000
Net income
-11m
L-25.45%
-15,042,000-12,292-33,769,000-19,590,000-23,470,000-29,122,000-26,992,000-11,694,000-16,954,000-8,432,000-14,604,000-15,198,000-11,330,000
CFO
-10m
L-18.32%
-11,992-15,007,000-18,269,000-24,997,000-31,226,000-22,165,000-15,772,000-8,755,000-11,156,000-14,688,000-12,054,000-9,846,000
Earnings
Jul 28, 2025

Profile

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
IPO date
Apr 10, 2013
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
17,925
-1.94%
18,279
41.57%
12,912
14.81%
Cost of revenue
28,385
33,391
28,468
Unusual Expense (Income)
NOPBT
(10,460)
(15,112)
(15,556)
NOPBT Margin
Operating Taxes
(476)
Tax Rate
NOPAT
(10,460)
(15,112)
(15,080)
Net income
(11,330)
-25.45%
(15,198)
4.07%
(14,604)
73.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,019
661
176
BB yield
-73.34%
-1.91%
-1.14%
Debt
Debt current
1,677
1,976
2,651
Long-term debt
4,733
6,641
6,282
Deferred revenue
2,169
1,032
Other long-term liabilities
2,102
471
374
Net debt
(83)
(21)
(11,592)
Cash flow
Cash from operating activities
(9,846)
(12,054)
(14,688)
CAPEX
(157)
(194)
Cash from investing activities
(37)
(157)
(5,175)
Cash from financing activities
7,769
348
176
FCF
(11,134)
(15,344)
(21,059)
Balance
Cash
6,493
8,638
20,525
Long term investments
Excess cash
5,597
7,724
19,879
Stockholders' equity
(249,496)
(238,974)
(223,371)
Invested Capital
270,288
261,508
257,724
ROIC
ROCE
EV
Common stock shares outstanding
20,161
13,867
12,962
Price
0.61
-75.60%
2.50
110.08%
1.19
-55.09%
Market cap
12,298
-64.53%
34,668
124.75%
15,425
-52.56%
EV
12,215
34,646
3,833
EBITDA
(8,852)
(13,414)
(14,669)
EV/EBITDA
Interest
269
302
156
Interest/NOPBT